01 February 2006
Venlafaxine HCl in the treatment of painful peripheral uremic neuropathy: a case report
Ali Kemal Kadiroglu, Dede Sit, Hasan Kayabasi, Emin Yilmaz, Bunyamin IsikogluCase Rep Clin Pract Rev 2006; 7:159-161 :: ID: 452156
Abstract
Background: It is well known that uremia may lead symmetric sensorimotor polyneuropathy that tends to
affect the lower limbs compared to upper limbs. It typically involves the legs than the arms. Clinical manifestations include paresthesia, painful dysesthesia, weakness in the legs and arms.
The traditional tricyclic antidepressants (TCA) are commonly used in the treatment of painful peripheral polyneuropathy. Venlafaxine is a serotonin noradrenaline reuptake inhibitor that may have analgesic effect on painful peripheral polyneuropathy.
Case Report: Venlafaxine extended release capsule (Effexor 75mg XR, Wyeth) was administered to a 49 years old female patient who has been under hemodialysis therapy for 7 years. She complained of
bilateral numbness, pain, pin-pricking and burning in her feet that increasing in the evening. She was also suffered from insomnia for two months. The patient’s symptoms were resolved in two weeks after beginning to the therapy but the intensity of pain continued minimaly and the patients demonstrated effective improvements at her insomnia in this period. Venlafaxine was well tolerated and there were no side effects such as nasuea, elevated blood pressure and
dizziness.
Conclusions: Venlafaxine relieved the symptoms of the uremic polyneuropathy and it was effective in
insomnia.
Keywords: Venlafaxine HCl, painful peripheral polyneuropathy, Uremia
In Press
08 Jun 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.939098
06 Jun 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.940200
05 Jun 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.939421
05 Jun 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.939292
Most Viewed Current Articles
06 Dec 2021 : Case report
DOI :10.12659/AJCR.934406
Am J Case Rep 2021; 22:e934406
13 Jul 2022 : Case report
DOI :10.12659/AJCR.936441
Am J Case Rep 2022; 23:e936441
07 Dec 2021 : Case report
DOI :10.12659/AJCR.934347
Am J Case Rep 2021; 22:e934347
23 Feb 2022 : Case report
DOI :10.12659/AJCR.935250
Am J Case Rep 2022; 23:e935250